A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH

A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH

Key Clinical Message Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on December 22, 2021, to treat COVID‐19. We describe a c...

Full description

Bibliographic Details
Main Authors: Sarah Mohamed, Mostafa Reda Mostafa, Mohamed Magdi Eid, Yossef Hassan AbdelQadir, Yomna Ali Abdelghafar, Sarya Swed, Bishara Jahshan, Waddah Abd El‐Radi
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Clinical Case Reports
Subjects:
COVID‐19
hyponatremia
nirmatrelvir‐ritonavir
PAXLOVID
SARS‐CoV‐2 virus
SIADH
Online Access:https://doi.org/10.1002/ccr3.7860

Internet

https://doi.org/10.1002/ccr3.7860

Similar Items